Zobrazeno 1 - 10
of 410
pro vyhledávání: '"O. Bayindir"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
E. Durak Ediboglu, D. Solmaz, H. Cinakli, G. Alp, E. Otman Akat, E. Erpek, İ. Kurut Aysin, S. Gucenmez, S. Ketenci, O. Bayindir, M. Ozmen, S. Akar
Publikováno v:
Annals of the Rheumatic Diseases. 81:1555.3-1556
BackgroundThe BASDAI is one of the basic scales used in the measurement of disease activity in patients with spondyloarthritis and allows the evalution of various aspects of the disease (axial and peripheral disease as well as inflammation). The pati
Autor:
M. Gulec Yazir, E. Durak Ediboglu, G. Alp, H. Cinakli, İ. Kurut Aysin, E. Erpek, E. Otman Akat, S. Gucenmez, M. Ozmen, S. Ketenci, O. Bayindir, D. Solmaz, S. Akar
Publikováno v:
Annals of the Rheumatic Diseases. 81:1512.2-1513
BackgroundPatient reported outcomes (BASDAI and BASFI) are used to evaluate disease activity in axial spondylarthritis (axSpA), however, apart from C-reactive protein (CRP) there are no widely used serum biomarkers to assess disease activity and trea
Autor:
Selen Bayraktaroglu, Gonca Karabulut, Mete Kara, Neşe Çelebisoy, O. Bayindir, Fahrettin Oksel, Hayriye Koçanaoğulları, Figen Yargucu Zihni
Publikováno v:
Volume: 57, Issue: 3 174-177
Ege Tıp Dergisi
Ege Tıp Dergisi
Granülomatöz polianjiit birçok sistemi tutan, hayatı tehdit eden bir hastalıktır. Tedavi stratejileri hastalığı iyileştirdiği gibi enfeksiyonlara yatkınlığı da arttırmaktadır. Enfeksiyonlar tanının ilk yılındaki en önemli ölüm
Autor:
S. Gucenmez, H. Cinakli, E. Erpek, Mustafa Özmen, Servet Akar, Dilek Solmaz, E. Otman Akat, G. Alp, G. Kabadayi, E. Durak Ediboglu, I. Kurut Aysin, O. Bayindir
Publikováno v:
Annals of the Rheumatic Diseases. 80:861-862
Background:On March 11, 2020, the World Health Organization declared coronavirus disease 2019 (COVID-19) as a pandemic, and mandatory quarantine was applied in Turkey between April and June 2020. With this sanction, sudden changes occurred in a routi
Autor:
S. Gucenmez, H. Cinakli, G. Alp, E. Durak Ediboglu, O. Bayindir, E. Otman Akat, Dilek Solmaz, G. Kabadayi, Servet Akar, I. Kurut Aysin, E. Erpek, Mustafa Özmen
Publikováno v:
Annals of the Rheumatic Diseases. 80:1255.1-1255
Background:Systemic sclerosis (SSc) is a devastating disease that has a profound impact on life expectancy, reflected by a standardised mortality ratio of 3,5. There is still limited data regarding the predictive factors for mortality in patients wit
Autor:
Umut Kalyoncu, Emel Gönüllü, Sibel Bakirci, M. Cinar, S. Ergulu Eşmen, Ahmet Omma, Cem Ozisler, Gezmiş Kimyon, Servet Akar, Meryem Can, Orhan Küçükşahin, Levent Kılıç, S. Pehlevan, Ediz Dalkilic, Senol Yavuz, Suna Aydin, Duygu Ersözlü, Dilek Solmaz, Esen Kasapoglu, Atalay Dogru, Mehmet Tuncay Duruöz, Abdurrahman Tufan, A. Erden, O. Bayindir, Fusun Yildiz, Sevdiye Ersoy Yilmaz, Emine Figen Tarhan
Publikováno v:
Annals of the Rheumatic Diseases. 79:1678.1-1678
Background:Although psoriatic arthritis (PsA) may be seen at any decades, juvenil onset PsA is relatively rare. Moreover, there were no more data about clinical features, treatments, and course in juvenile PsA when they reached to adult age.Objective
Autor:
G. Kabadayi, S. Gucenmez, Dilek Solmaz, O. Bayindir, E. Durak Ediboglu, E. Otman Akat, I. Kurut Aysin, Mustafa Özmen, H. Cinakli, Servet Akar, H. E. Oz
Publikováno v:
Annals of the Rheumatic Diseases. 79:1623-1623
Background:Axial spondyloarthritis (axSpA) is a chronic inflammatory condition affecting mainly axial skeleton. The disease usually starts in early adulthood and cause considerable impact on physical function, work ability and quality of life (QoL).